HIV coinfection with hepatitis c laboratory findings: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{HIV coinfection with hepatitis c}} {{CMG}} ==Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009<ref name=...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{HIV coinfection with hepatitis c}}
{{HIV coinfection with hepatitis c}}
{{CMG}}


==Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>==
Please help WikiDoc by adding content here. It's easy!  Click [[Help:How_to_Edit_a_Page|here]] to learn about editing.
{{cquote|
'''1.''' Anti-HCV testing should be performed in all HIV-infected persons ''(Class I, Level B)''.
 
'''2.''' HCV RNA testing should be performed to confirm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease ''(Class I, Level B)''.
 
'''3.''' Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy ''(Class I, Level A)''.
 
'''4.''' Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients ''(Class I, Level A)''.
 
'''5.''' When possible, patients receiving [[zidovudine]] (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin ''(Class I, Level C)''.
 
'''6.''' HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation ''(Class IIa, Level C)''.}}


==References==
==References==
Line 22: Line 9:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Needs overview]]
[[Category:Needs content]]

Revision as of 16:26, 7 December 2012